| CTAS |
Report |
Q4 revenue |
IN-LINE |
pred ~$2.89B vs. cons $2.87B |
MEDIUM |
| CTAS |
Report |
Q4 adjusted diluted EPS |
BEAT |
pred ~$1.28 vs. cons $1.25 |
MEDIUM |
| CTAS |
Report |
Q4 organic revenue growth |
IN-LINE |
pred ~7.8% vs. cons 7.6% |
MEDIUM |
| CTAS |
Guide |
FY2027 revenue guidance |
LOWER |
guide ~$11.98B vs. cons $12.05B (FY2027) |
MEDIUM |
| CTAS |
Guide |
FY2027 adjusted diluted EPS guidance |
LOWER |
guide ~$5.33 vs. cons $5.49 (FY2027) |
MEDIUM |
| CTAS |
Guide |
UniFirst closing timetable |
UNCHANGED |
guide ~2H 2026 vs. cons 2H 2026 (calendar 2026) |
LOW |
| CTAS |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.5% |
— |
MEDIUM |
| CTAS |
Return |
5-day cumulative residual |
-6.5% (FOLLOW-THROUGH) |
A modest Q4 EPS beat of ~$1.28 versus $1.25 is unlikely to offset FY2027 EPS guidance of ~$5.33 versus $5.49 consensus; the ~$0.16 out-period reset should drive estimate cuts and valuation de-rating even if core organic growth is near 7.8% versus 7.6%. |
MEDIUM |